Oric Pharmaceuticals Inc at Goldman Sachs Healthcare Conference Transcript
Great. Good morning, everyone. Thanks for joining us here at the Goldman Sachs Global Healthcare Conference. And good morning on our second day of event ever who's joining us online as well. And we're thrilled to have the team from ORIC here this morning, and we'll just get right into it.
Questions & Answers
Maybe to start, there was some news last week, not from you guys but from Fulcrum, which was an update that has obviously been top of mind given the mechanism of action overlap. Maybe you could speak to the Fulcrum update on pociredir and any potential implications for your program in prostate cancer in Rinzimetostat?
Yes. Firstly, thanks for having us here at the conference. So I just got a conference. We're just talking about the long flight across the country. So at a high level, last week, Fulcrum announced the discontinuation of their PRC2 inhibitor, which they were studying in sickle cell disease.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
